Liu Mingtao, Liu Li, Chen Jiaxi, Huang Zhifeng, Zhu Huiqing, Lin Shengxuan, Qi Weitian, Cheng Zhangkai J, Li Ning, Sun Baoqing
Department of Clinical Laboratory, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510140, China.
KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou 511495, China.
J Zhejiang Univ Sci B. 2025 Jan 18;26(2):158-171. doi: 10.1631/jzus.B2300433.
The accurate and timely detection of biochemical coagulation indicators is pivotal in pulmonary and critical care medicine. Despite their reliability, traditional laboratories often lag in terms of rapid diagnosis. Point-of-care testing (POCT) has emerged as a promising alternative, which is awaiting rigorous validation. We assessed 226 samples from patients at the First Affiliated Hospital of Guangzhou Medical University using a Beckman Coulter AU5821 and a PUSHKANG POCT Biochemistry Analyzer MS100. Furthermore, 350 samples were evaluated with a Stago coagulation analyzer STAR MAX and a PUSHKANG POCT Coagulation Analyzer MC100. Metrics included thirteen biochemical indexes, such as albumin, and five coagulation indices, such as prothrombin time. Comparisons were drawn against the PUSHKANG POCT analyzer. Bland-Altman plots (MS100: 0.8206‒0.9995; MC100: 0.8318‒0.9911) evinced significant consistency between methodologies. Spearman correlation pinpointed a potent linear association between conventional devices and the PUSHKANG POCT analyzer, further underscored by a robust correlation coefficient (MS100: 0.713‒0.949; MC100: 0.593‒0.950). The PUSHKANG POCT was validated as a dependable tool for serum and whole blood biochemical and coagulation diagnostics. This emphasizes its prospective clinical efficacy, offering clinicians a swift diagnostic tool and heralding a new era of enhanced patient care outcomes.
准确及时地检测生化凝血指标在肺病和重症医学中至关重要。尽管传统实验室可靠，但在快速诊断方面往往滞后。即时检验（POCT）已成为一种有前景的替代方法，尚待严格验证。我们使用贝克曼库尔特AU5821和普康POCT生化分析仪MS100对广州医科大学附属第一医院患者的226份样本进行了评估。此外，还使用思塔高凝血分析仪STAR MAX和普康POCT凝血分析仪MC100对350份样本进行了评估。指标包括白蛋白等13项生化指标以及凝血酶原时间等5项凝血指标。与普康POCT分析仪进行了比较。布兰德-奥特曼图（MS100：0.8206‒0.9995；MC100：0.8318‒0.9911）表明方法之间具有显著一致性。Spearman相关性确定了传统设备与普康POCT分析仪之间存在强线性关联，强大的相关系数进一步强调了这一点（MS100：0.713‒0.949；MC100：0.593‒0.950）。普康POCT被验证为血清和全血生化及凝血诊断的可靠工具。这突出了其潜在的临床疗效，为临床医生提供了一种快速诊断工具，并预示着提高患者护理结果的新时代。
